tirzepatide and heart disease Cardiovascular effects of Tirzepatide and Cardiovascular Outcomes: A

I love how the plan is physician-supervised

These findings align with the results of the SUSTAIN-6 and PIONEER-6 trials, showing a 26% and non-significant 21% reduction, respectively, in the hazard ratio of major adverse cardiovascular events (MACE) in T2D populations with high CV risk

The authors discussed the possibility that both skin and muscles can be pain generators in the body

Tirzepatide met the criteria for superiority compared with a putative placebo on the rate of the primary composite endpoint of cardiovascular death, myocardial infarction or stroke

Cardiovascular Protection GLP-1s lower inflammation, improve endothelial function, and reduce cardiovascular eventsindependent of weight loss